DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
27.00B
Market cap27.00B
Price-Earnings ratio
30.00
Price-Earnings ratio30.00
Dividend yield
Dividend yield
Average volume
5.22M
Average volume5.22M
High today
$71.06
High today$71.06
Low today
$69.46
Low today$69.46
Open price
$69.67
Open price$69.67
Volume
3.97M
Volume3.97M
52 Week high
$89.98
52 Week high$89.98
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $69.98. The company's market cap stands at 27B, with a P/E ratio of 30.00.

As of 2026-06-30, DexCom(DXCM) stock has fluctuated between $69.46 and $71.06. The current price stands at $69.98, placing the stock +0.7% above today's low and -1.5% off the high.

The DexCom(DXCM)'s current trading volume is 3.97M, compared to an average daily volume of 5.22M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

DXCM News

Simply Wall St 54m
Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's Investment Narrative?

DexCom recently received FDA clearance to expand use of its Stelo Glucose Biosensor to children aged 2 and older who do not use insulin, and it is preparing to...

Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's Investment Narrative?
Simply Wall St 1d
Is DexCom A Bargain On FDA Cleared Stelo Expansion?

Advertisement FDA clearance for Stelo expansion puts DexCom (DXCM) back in focus DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use...

Is DexCom A Bargain On FDA Cleared Stelo Expansion?
Simply Wall St 3d
DexCom Launches New Stelo App As It Expands Into Four Countries

DexCom is rolling out a redesigned Stelo app in July that aims to provide more accessible and actionable glucose insights to users. The company is preparing to...

DexCom Launches New Stelo App As It Expands Into Four Countries

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
15.6%
Sell
0%

More DXCM News

TipRanks 7d
DexCom initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of DexCom (DXCM) with a Buy rating and $86 price target The company “could be turning a corner” as its recent investor day ease...

TipRanks 7d
DexCom announces milestones to make glucose biosensing more accessible

DexCom (DXCM) announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. The company announce...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.